The discovery of molecular targets mediated by BRD4 inhibition provides important insights into the potential mechanisms of sunitinib resistance, new therapeutics, and novel biomarkers in ccRCC. The gene discussed is BRD4; the disease is nonpapillary renal cell carcinoma.